CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
18F-FDG PET/CTradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03683355
NCT03683355N/ACompleted

Characterization of Radiolabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves. The COUNT Study. A Prospective, Observational Study.

In Brief

An observational study evaluating 18F-FDG PET/CT for Infective Endocarditis. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Therefore, the objective of the study is to characterize the pattern of radiolabeled tracer (18F-FDG) uptake in noninfected transcatheter heart valves in early follow-up after transcatheter aortic valve replacement (TAVR).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 25, 2018
Enrollment StartNov 9, 2018
Primary CompletionMar 1, 2022
Study CompletionMar 1, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.8 years ago

Interventions

18F-FDG PET/CTradiation

18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.